202 related articles for article (PubMed ID: 30986523)
21. Clinical outcomes of elderly patients with bloodstream infections due to extended-spectrum β-lactamase-producing Enterobacteriaceae in an Italian Internal Medicine ward.
Meini S; Laureano R; Tascini C; Arena F; Fani L; Frullini A; Passaleva MT; Roberts AT; Mannini D; Sbrana F; Ripoli A; Rossolini GM
Eur J Intern Med; 2018 Feb; 48():50-56. PubMed ID: 29089174
[TBL] [Abstract][Full Text] [Related]
22. Extended-spectrum β-lactamase-producing Enterobacteriaceae, national study of antimicrobial treatment for pediatric urinary tract infection.
Lagree M; Bontemps S; Dessein R; Angoulvant F; Madhi F; Martinot A; Cohen R; Dubos F;
Med Mal Infect; 2018 May; 48(3):193-201. PubMed ID: 29449049
[TBL] [Abstract][Full Text] [Related]
23. Management of infections caused by extended-spectrum β-lactamase-producing Enterobacteriaceae: current evidence and future prospects.
Sheu CC; Lin SY; Chang YT; Lee CY; Chen YH; Hsueh PR
Expert Rev Anti Infect Ther; 2018 Mar; 16(3):205-218. PubMed ID: 29402125
[TBL] [Abstract][Full Text] [Related]
24. Efficacy of β-Lactam/β-Lactamase Inhibitor Combinations for the Treatment of Bloodstream Infection Due to Extended-Spectrum-β-Lactamase-Producing Enterobacteriaceae in Hematological Patients with Neutropenia.
Gudiol C; Royo-Cebrecos C; Abdala E; Akova M; Álvarez R; Maestro-de la Calle G; Cano A; Cervera C; Clemente WT; Martín-Dávila P; Freifeld A; Gómez L; Gottlieb T; Gurguí M; Herrera F; Manzur A; Maschmeyer G; Meije Y; Montejo M; Peghin M; Rodríguez-Baño J; Ruiz-Camps I; Sukiennik TC; Tebe C; Carratalà J;
Antimicrob Agents Chemother; 2017 Aug; 61(8):. PubMed ID: 28584145
[TBL] [Abstract][Full Text] [Related]
25. National multicenter study of predictors and outcomes of bacteremia upon hospital admission caused by Enterobacteriaceae producing extended-spectrum beta-lactamases.
Marchaim D; Gottesman T; Schwartz O; Korem M; Maor Y; Rahav G; Karplus R; Lazarovitch T; Braun E; Sprecher H; Lachish T; Wiener-Well Y; Alon D; Chowers M; Ciobotaro P; Bardenstein R; Paz A; Potasman I; Giladi M; Schechner V; Schwaber MJ; Klarfeld-Lidji S; Carmeli Y
Antimicrob Agents Chemother; 2010 Dec; 54(12):5099-104. PubMed ID: 20837757
[TBL] [Abstract][Full Text] [Related]
26. Efficacy of empirical therapy with non-carbapenems for urinary tract infections with extended-spectrum beta-lactamase-producing Enterobacteriaceae.
Asakura T; Ikeda M; Nakamura A; Kodera S
Int J Infect Dis; 2014 Dec; 29():91-5. PubMed ID: 25461239
[TBL] [Abstract][Full Text] [Related]
27. Duration of colonization by extended-spectrum β-lactamase-producing Enterobacteriaceae after hospital discharge.
Birgand G; Armand-Lefevre L; Lolom I; Ruppe E; Andremont A; Lucet JC
Am J Infect Control; 2013 May; 41(5):443-7. PubMed ID: 22998785
[TBL] [Abstract][Full Text] [Related]
28. The Activity of Fosfomycin Against Extended-Spectrum Beta-Lactamase-Producing Isolates of Enterobacteriaceae Recovered from Urinary Tract Infections: A Single-Center Study Over a Period of 12 Years.
Aris P; Boroumand MA; Rahbar M; Douraghi M
Microb Drug Resist; 2018 Jun; 24(5):607-612. PubMed ID: 29064348
[TBL] [Abstract][Full Text] [Related]
29. Clinical significance and impact on mortality of extended-spectrum beta lactamase-producing Enterobacteriaceae isolates in nosocomial bacteremia.
Menashe G; Borer A; Yagupsky P; Peled N; Gilad J; Fraser D; Riesenberg K; Schlaeffer F
Scand J Infect Dis; 2001; 33(3):188-93. PubMed ID: 11303808
[TBL] [Abstract][Full Text] [Related]
30. Comparison of fosfomycin to ertapenem for outpatient or step-down therapy of extended-spectrum β-lactamase urinary tract infections.
Veve MP; Wagner JL; Kenney RM; Grunwald JL; Davis SL
Int J Antimicrob Agents; 2016 Jul; 48(1):56-60. PubMed ID: 27234673
[TBL] [Abstract][Full Text] [Related]
31. Inappropriate empirical antibiotic therapy does not adversely affect the clinical outcomes of patients with acute pyelonephritis caused by extended-spectrum β-lactamase-producing Enterobacteriales.
Kim SH; Oh S; Huh K; Cho SY; Kang CI; Chung DR; Peck KR
Eur J Clin Microbiol Infect Dis; 2019 May; 38(5):937-944. PubMed ID: 30868326
[TBL] [Abstract][Full Text] [Related]
32. International travel is a risk factor for extended-spectrum β-lactamase-producing Enterobacteriaceae acquisition in children: A case-case-control study in an urban U.S. hospital.
Strysko JP; Mony V; Cleveland J; Siddiqui H; Homel P; Gagliardo C
Travel Med Infect Dis; 2016; 14(6):568-571. PubMed ID: 27890813
[TBL] [Abstract][Full Text] [Related]
33. Extended spectrum beta-lactamase-producing Enterobacteriaceae infections in hematopoietic stem cell transplant recipients: Epidemiology and molecular characterization.
Kharrat M; Chebbi Y; Ben Tanfous F; Lakhal A; Ladeb S; Othmen TB; Achour W
Int J Antimicrob Agents; 2018 Dec; 52(6):886-892. PubMed ID: 29783023
[TBL] [Abstract][Full Text] [Related]
34. Extended spectrum β-lactamase producing enterobacteriaceae: carbapenem sparing options.
Aslan AT; Akova M
Expert Rev Anti Infect Ther; 2019 Dec; 17(12):969-981. PubMed ID: 31722185
[No Abstract] [Full Text] [Related]
35. Extended-spectrum beta-lactamase-producing organisms.
Falagas ME; Karageorgopoulos DE
J Hosp Infect; 2009 Dec; 73(4):345-54. PubMed ID: 19596491
[TBL] [Abstract][Full Text] [Related]
36. Does Quick Sepsis-Related Organ Failure Assessment Suggest the Use of Initial Empirical Carbapenem Therapy in Bacteremia Caused by Extended-Spectrum β-Lactamase-Producing Bacteria? :A Multicenter Case-Control Study.
Mitsuboshi S; Tsuruma N; Watanabe K; Takahashi S; Nakashita M; Ito A; Kobayashi K; Tsugita M
Jpn J Infect Dis; 2019 Mar; 72(2):124-126. PubMed ID: 30381688
[TBL] [Abstract][Full Text] [Related]
37. A multinational survey of risk factors for infection with extended-spectrum beta-lactamase-producing enterobacteriaceae in nonhospitalized patients.
Ben-Ami R; Rodríguez-Baño J; Arslan H; Pitout JD; Quentin C; Calbo ES; Azap OK; Arpin C; Pascual A; Livermore DM; Garau J; Carmeli Y
Clin Infect Dis; 2009 Sep; 49(5):682-90. PubMed ID: 19622043
[TBL] [Abstract][Full Text] [Related]
38. Development and validation of the INCREMENT-ESBL predictive score for mortality in patients with bloodstream infections due to extended-spectrum-β-lactamase-producing Enterobacteriaceae.
Palacios-Baena ZR; Gutiérrez-Gutiérrez B; De Cueto M; Viale P; Venditti M; Hernández-Torres A; Oliver A; Martínez-Martínez L; Calbo E; Pintado V; Gasch O; Almirante B; Antonio Lepe J; Pitout J; Akova M; Peña-Miralles C; Schwaber MJ; Tumbarello M; Tacconelli E; Origüen J; Prim N; Bou G; Giamarellou H; Bermejo J; Hamprecht A; Pérez F; Almela M; Lowman W; Hsueh PR; Navarro-San Francisco C; Torre-Cisneros J; Carmeli Y; Bonomo RA; Paterson DL; Pascual Á; Rodríguez-Baño J;
J Antimicrob Chemother; 2017 Mar; 72(3):906-913. PubMed ID: 28062685
[TBL] [Abstract][Full Text] [Related]
39. Which proportion of extended-spectrum beta-lactamase producing strains could be treated by non-carbapenem beta-lactams?
Canoui E; Tankovic J; Bige N; Alves M; Offenstadt G
Med Mal Infect; 2014 May; 44(5):235-7. PubMed ID: 24780641
[No Abstract] [Full Text] [Related]
40. Cefmetazole for extended-spectrum β-lactamase-producing Enterobacteriaceae in pediatric pyelonephritis.
Araki K; Fukuoka K; Higuchi H; Aizawa Y; Horikoshi Y
Pediatr Int; 2019 Jun; 61(6):572-577. PubMed ID: 30908807
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
